Biosimilar Market Analysis

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Caspofungin biosimilars approved in Europe are the most active HAI-specific biosimilar category. Biosimilar interchangeability designation from FDA, when granted for anti-infective biologics, would accelerate automatic substitution at the hospital pharmacy level and accelerate the erosion curve for originator net price. Claritas estimates biosimilar caspofungin erodes originator net price 15–20% over a 3-year post-entry period (Claritas model).